Sanofi India Beheer

Hoe is Rodolfo Hrosz's beloning veranderd ten opzichte van Sanofi India's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	₹5b
Jun 30 2024	n/a	n/a	₹5b
Mar 31 2024	n/a	n/a	₹5b
Dec 31 2023	₹36m	₹23m	₹6b
Sep 30 2023	n/a	n/a	₹6b
Jun 30 2023	n/a	n/a	₹6b
Mar 31 2023	n/a	n/a	₹6b
Dec 31 2022	₹18m	₹13m	₹6b

Compensatie versus markt: De totale vergoeding ($USD 430.75K ) Rodolfo } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 481.78K ).

Compensatie versus inkomsten: De beloning van Rodolfo is het afgelopen jaar met meer dan 20% gestegen, terwijl de winst van het bedrijf met meer dan 20% is gedaald.

CEO

Rodolfo Hrosz (57 yo)

2.4yrs

Tenure

₹36,390,000

Compensatie

Mr. Rodolfo Hrosz serves as Managing Director and Director for Sanofi India Limited since June 1, 2022. He joined Sanofi as General Manager of the Consumer Healthcare business in Brazil in 2017 and has suc...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Rodolfo Hrosz	MD & Director	2.4yrs	₹36.39m	geen gegevens
Rachid Ayari	CFO & Whole Time Director	less than a year	₹1.51m	geen gegevens
Renee Amonkar	Additional Whole Time Director	1.2yrs	₹1.85m	geen gegevens
M. Narayanaswamy	Senior Director of Accounting & Taxation	40.8yrs	geen gegevens	geen gegevens
Flovie Martins	Head of Corporate Communications & Corporate Social Responsibility	less than a year	geen gegevens	geen gegevens
Surabhi Kaur	People & Culture Director	1.1yrs	geen gegevens	geen gegevens
Sanjay Chavan	Head of Country Procurement - India	10.8yrs	geen gegevens	geen gegevens
Nakul Verma	Senior Director of Public Affairs	no data	geen gegevens	geen gegevens
Yasmin Shenoy	Senior Director of Regulatory Affairs	no data	geen gegevens	geen gegevens
N. Babu	Sales & Customer Engagement Head - Diabetes and Senior Director of Diabetes	no data	geen gegevens	geen gegevens

1.2yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van SANOFI wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.2 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Rodolfo Hrosz	MD & Director	2.4yrs	₹36.39m	geen gegevens
Rachid Ayari	CFO & Whole Time Director	less than a year	₹1.51m	geen gegevens
Renee Amonkar	Additional Whole Time Director	1.2yrs	₹1.85m	geen gegevens
Usha Thorat	Independent Non-Executive Director	8.6yrs	₹2.00m	geen gegevens
Rahul Bhatnagar	Independent Director	4.3yrs	₹3.00m	geen gegevens
Aditya Narayan	Independent Non-Executive Chairman	8.6yrs	₹4.00m	geen gegevens
Vaibhav Karandikar	Non-Executive Director	3.8yrs	₹20.23m	geen gegevens

3.8yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SANOFI wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Sanofi India Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Sanofi India Limited Announces Resignation of Radhika Shah as Head of Legal and Company Secretary

Sanofi India Limited Announces Cessation of Cyrus Aibara as Senior Director Diabetes

Sanofi India Limited Announces Resignation of Nitin Joshi, Head - Supply Chain, Effective 31 July 2024

Sanofi India Limited Announces Resignation of Shalini Menon, General Medicines Medical Head and India Medical Lead, Effective July 5, 2024

Less than half of directors are independent

Sanofi India Limited Appoints N. Suresh Babu as Sales & Customer Engagement Head Diabetes, Effective July 1, 2024

Recent updates

Third quarter 2024 earnings released: EPS: ₹35.69 (vs ₹65.95 in 3Q 2023)

Sanofi India Limited to Report Q3, 2024 Results on Nov 07, 2024

Sanofi India Limited Announces Resignation of Radhika Shah as Head of Legal and Company Secretary

Sanofi India Limited Announces Cessation of Cyrus Aibara as Senior Director Diabetes

Price target decreased by 9.1% to ₹8,501

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: EPS: ₹29.61 (vs ₹53.37 in 2Q 2023)

Sanofi India Limited Announces Resignation of Nitin Joshi, Head - Supply Chain, Effective 31 July 2024

Sanofi India Limited to Report Q2, 2024 Results on Jul 26, 2024

Sanofi India Limited Announces Resignation of Shalini Menon, General Medicines Medical Head and India Medical Lead, Effective July 5, 2024

Less than half of directors are independent

Sanofi India Limited Appoints N. Suresh Babu as Sales & Customer Engagement Head Diabetes, Effective July 1, 2024

New major risk - Share price stability

Investor sentiment improves as stock rises 17%

Sanofi India Limited's (NSE:SANOFI) 25% Share Price Surge Not Quite Adding Up

Sanofi India Limited Announces Resignation of Shalini Menon as General Medicines Medical Head and India Medical Lead

First quarter 2024 earnings released: EPS: ₹59.31 (vs ₹82.67 in 1Q 2023)

Upcoming dividend of ₹117 per share

Sanofi India (NSE:SANOFI) Will Pay A Dividend Of ₹117.00

Sanofi India Limited Announces Appointment of Flovie Martins as Head of Corporate Communications and Corporate Social Responsibility

Sanofi India (NSE:SANOFI) Will Pay A Dividend Of ₹117.00

Sanofi India Limited Announces Resignation of Marc-Antoine Lucchini as Non-Executive Director from the Board of Directors, Member of the Nomination and Remuneration Committee

Sanofi India (NSE:SANOFI) Is Due To Pay A Dividend Of ₹117.00

Sanofi India Limited Announces Resignation of Marc-Antoine Lucchini as Non-Executive Director, Member of the Nomination and Remuneration Committee

Sanofi India's (NSE:SANOFI) Dividend Will Be ₹117.00

Final dividend of ₹117 announced

Upcoming dividend of ₹50.00 per share

Price target increased by 8.8% to ₹9,371

Full year 2023 earnings released: EPS: ₹262 (vs ₹269 in FY 2022)

Sanofi India Limited, Annual General Meeting, May 14, 2024

Sanofi India Limited Recommends Final Dividend for the Financial Year Ended 31St December 2023, Payable on or After 24 May 2024

Sanofi India Limited to Report Q4, 2023 Results on Feb 23, 2024

Sanofi India Limited Appoints Radhika Shah as Head of Legal, Effective 15 January 2024

Risks To Shareholder Returns Are Elevated At These Prices For Sanofi India Limited (NSE:SANOFI)

Price target increased by 12% to ₹8,392

Third quarter 2023 earnings released: EPS: ₹65.95 (vs ₹56.84 in 3Q 2022)

Sanofi India Limited Announces the Resignation of Vaibhav Karandikar as Whole-Time Director

Sanofi India Limited to Report Q3, 2023 Results on Nov 08, 2023

Sanofi India Limited Appoints Surabhi Kaul as India People Director and Will Be Part of the Senior Management Personnel

Less than half of directors are independent

Sanofi India Limited Announces Executive Changes

Sanofi India Limited Announces Resignation of Vinita Korti Patil as Senior Legal Director - South Asia, Effective 7 December 2023

Second quarter 2023 earnings released: EPS: ₹53.37 (vs ₹52.28 in 2Q 2022)

Sanofi India Limited Announces Resignation of Gaurav Bahadur as People Director

Less than half of directors are independent

Sanofi India Limited to Report Q2, 2023 Results on Aug 10, 2023

Sanofi India Limited Announces Resignation of Annapurna Das as Non-Executive Director and Member of the Audit Committee, Effective 31 July 2023

Is Sanofi India (NSE:SANOFI) A Risky Investment?

Price target increased by 7.6% to ₹6,996

Full year 2022 earnings released: EPS: ₹269 (vs ₹410 in FY 2021)

Price target decreased by 7.9% to ₹6,604

Price target decreased by 8.5% to ₹6,986

Sanofi India Limited to Report Q4, 2022 Results on Feb 23, 2023

High number of new directors

Third quarter 2022 earnings released: EPS: ₹56.84 (vs ₹230 in 3Q 2021)

Sanofi India Limited Announces Change in Directorate

Sanofi India Limited to Report Q3, 2022 Results on Nov 03, 2022

Upcoming dividend of ₹193 per share

Price target decreased to ₹7,800

Second quarter 2022 earnings released: EPS: ₹52.28 (vs ₹77.42 in 2Q 2021)

Sanofi India Limited Approves One-Time Special Interim Dividend, Payable on August 22, 2022

Sanofi India Limited to Report Q2, 2022 Results on Jul 26, 2022

Does Sanofi India (NSE:SANOFI) Have A Healthy Balance Sheet?

First quarter 2022 earnings released: EPS: ₹104 (vs ₹63.35 in 1Q 2021)

Less than half of directors are independent

Sanofi India Appoints Rodolfo Hrosz as Managing Director

Sanofi India Limited to Report Q1, 2022 Results on Apr 26, 2022

Upcoming dividend of ₹490 per share

Full year 2021 earnings released: EPS: ₹410 (vs ₹207 in FY 2020)